Top Banner Top Banner

1. Tuettenberg J, Friedel C, Vajkoezy P. Angiogenesis in malignant glioma—A target for antitumor therapy? Critical Rev in Onc/Hematol 2006;59:181-193.

2. Gerstner ER, Duda DG, di Tomaso, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009;6:229-236.

3. Wagner SA, Desjardins A, Reardon DA, et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. J Clin Oncol 2008;26(15s):abstr 2021.

4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.

5. Lai A, Nghiemphu P, Green R, et al. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2009;27(15s):abstr 2000.

6. Stupp R, Mason WP, van den Brent MJ, et al. Radiotherapy plus conconmitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.

7. Batchelor T, Sorensen AG, Ancukiewicz M, et al. A Phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2007;25(18S):abstr 2001.

8. Reardon DA, Fink KL, Mikkelsen, et al. Randomized phase study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-5617.

9. Lacouture ME, Lenihan DJ, Quaggin SE. Targeting Tumor Angiogenesis, Summer 2009. Antiangiogenic therapy: tolerability and management of side effects. The Angiogenesis Foundation, 2009.

10. System ENABLE™.

Last updated March 1, 2012